Cosentyx holding its own against Stelara, rheumatologists say

17 May 2017

A study involving 1,000 US patients with psoriatic arthritis offers insight into the evolving market landscape in this therapy area.

Prepared by market intelligence agency Spherix, the report collates input from 200 healthcare professionals and looks at patients who were recently switched between biologic brands and/or Otezla (apremilast).

The data show that Cosentyx (secukinumab), from Swiss pharma giant Novartis (NOVN: VX), managed to hold Johnson & Johnson subsidiary (NYSE: JNJ) Janssen's Stelara (ustekinumab) to a 9% share of all recent treatment switches.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK